Sign up to save your podcasts
Or
Share Treatment of Metastatic Non-Small Cell Lung Cancer With Targeted Mutations
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Treatment of Metastatic Non-Small Cell Lung Cancer With Targeted Mutations
Join us in this episode of the Oncology Brothers podcast as we dive deep into the rapidly evolving treatment landscape for metastatic non-small cell lung cancer (NSCLC) with actionable mutations in frontline therapy. Hosted by community oncologists Drs. Rahul and Rohit Gosain, we are thrilled to welcome Dr. Susan Scott, a thoracic medical oncologist from the Johns Hopkins Hospital.
In this episode, we covered:
• Common EGFR mutations and the latest treatment options, including osimertinib, amivantamab, and chemotherapy combinations.
• The importance of comprehensive NGS testing and the need for retesting at progression.
• Insights into managing side effects associated with various therapies, including the proactive management of cutaneous toxicities.
• Treatment strategies for less common mutations such as ALK, ROS1, BRAF, and RET, along with their respective targeted therapies.
• The role of immunotherapy in specific mutations and the importance of patient choice and preferences in treatment decisions.
Whether you're a practicing oncologist or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information to help guide your practice.
YouTube: https://youtu.be/LMYDAjZcn5w
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
View all episodes
By Oncology Brothers
4.8
3636 ratings
Join us in this episode of the Oncology Brothers podcast as we dive deep into the rapidly evolving treatment landscape for metastatic non-small cell lung cancer (NSCLC) with actionable mutations in frontline therapy. Hosted by community oncologists Drs. Rahul and Rohit Gosain, we are thrilled to welcome Dr. Susan Scott, a thoracic medical oncologist from the Johns Hopkins Hospital.
In this episode, we covered:
• Common EGFR mutations and the latest treatment options, including osimertinib, amivantamab, and chemotherapy combinations.
• The importance of comprehensive NGS testing and the need for retesting at progression.
• Insights into managing side effects associated with various therapies, including the proactive management of cutaneous toxicities.
• Treatment strategies for less common mutations such as ALK, ROS1, BRAF, and RET, along with their respective targeted therapies.
• The role of immunotherapy in specific mutations and the importance of patient choice and preferences in treatment decisions.
Whether you're a practicing oncologist or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information to help guide your practice.
YouTube: https://youtu.be/LMYDAjZcn5w
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
Breast Cancer Update
63 Listeners
Journal of Clinical Oncology (JCO) Podcast
41 Listeners
Research To Practice | Oncology Videos
114 Listeners
The NPR Politics Podcast
25,756 Listeners
ASCO Daily News
56 Listeners
The Curbsiders Internal Medicine Podcast
3,314 Listeners
Core IM | Internal Medicine Podcast
1,090 Listeners
OncoPharm
184 Listeners
ASCO Guidelines
43 Listeners
OncLive® On Air
21 Listeners
The Clinical Problem Solvers
508 Listeners
Run the List
243 Listeners
Oncology Today with Dr Neil Love
53 Listeners
Two Onc Docs
166 Listeners
Blood Cancer Talks
48 Listeners